SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge driven by intense market speculation regarding new commercial partnerships in the AI optical interconnect space, further fueled by a significant short squeeze. The community is actively debating the sustainability of the company's valuation against its current revenue, while many are focused on the impact of potential institutional accumulation and the scarcity of available shares for shorting.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intensified volatility as investors weigh a major workforce efficiency shift alongside broader software sector weakness, with market attention laser-focused on upcoming earnings for signals that AI infrastructure investments are successfully translating into Azure revenue growth.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is currently drawing significant community attention following the release of Phase 2/3 trial data for tovecimig, which met its primary efficacy endpoint in biliary tract cancer despite failing to reach statistical significance on the overall survival secondary endpoint. Investors are actively debating the company's robust balance sheet and regulatory pathway, weighing the clinical benefit against the uncertainty surrounding the study's crossover-confounded survival results.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant momentum as investors anticipate major catalysts, including an upcoming oral presentation of pancreatic cancer data at Digestive Disease Week and multiple ongoing clinical trial milestones. The community is actively discussing the company's progress in targeting difficult-to-treat solid tumors, with many viewing the current valuation as an accumulation opportunity ahead of potential data readouts.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following the release of positive pivotal trial data for its in vivo CRISPR-based hereditary angioedema treatment, which has sparked significant debate regarding its commercial potential compared to existing therapies. While the community is actively discussing the validation of the company's gene-editing platform, the stock's price action remains volatile as investors weigh the breakthrough clinical results against concerns about market competition and future reimbursement.

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy (GLND) is surging as community sentiment centers on a major drilling partnership with Halliburton for a 2026 campaign in the Jameson Land Basin, which investors view as a pivotal validation of the company's Arctic oil and mineral assets. Discussions are heavily focused on the stock's low float, extreme short interest, and the potential for a significant squeeze amid heightened global interest in energy security.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is trending following positive interim Phase 2a results for ORKA-001 in psoriasis, which hit its primary endpoint and showed potential for annual dosing. The community is actively debating the company's long-term valuation compared to sector peers and monitoring potential dilution as the firm moves toward larger late-stage trials.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is trending as the market processes the company's strategic decision to prioritize its acne program, including the upcoming initiation of a Phase 3 trial, alongside a successful capital raise of $175 million. The community is actively debating the impact of this significant equity offering on dilution versus the potential validation of the company's long-term commercial runway and accelerated development timeline for denifanstat.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors react to a significant revenue outlook miss for the upcoming quarter and broader memory supply constraints that are pressuring smartphone handset sales. Community sentiment is deeply divided, with many debating the impact of these headwinds versus the potential for long-term growth through AI-powered smartphone chips, upcoming automotive design wins, and aggressive stock buyback programs.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors digest news of an expanded collaboration with Synopsys aimed at accelerating GaN-based power and RF semiconductor development. While some community members remain skeptical due to the company's long-standing pre-revenue status, others point to active wafer runs and institutional buying as signs that commercial validation is imminent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The main goal of the study is to evaluate safety, feasibility, and tolerability, track tumor response, disease progression, and survival outcomes</li><li>The biotech firm also marked the debut of its Alpha DaRT therapy for pancreatic cancer in Europe.</li></ul>Shares of Alpha Tau Medical (DRTS) drew strong retail attention on Friday, rising nearly 4% in pre-market trading after the company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.On Thursday, the U.S. Food and Drug Administration (FDA) cleared an Investigational Device Exemption (IDE) supplement to expand its pancreatic cancer study, known as the IMPACT trial, which is testing its Alpha DaRT therapy alongside chemotherapy.The update allows the company to enroll 10 additional patients receiving the chemotherapy combination Gemcitabine and Abraxane, split evenly between locally advanced and metastatic pancreatic cancer cases. This expansion takes the total enrollment to 40 patients.The IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma. The main goal of the study is to evaluate safety, feasibility, and tolerability, while also tracking tumor response, disease progression, survival outcomes, and patient-reported pain relief.<h2 class="st-heading-2">Retail Bullish On Trial Expansion</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/DRTS">DRTS</a> on Stocktwits turned ‘bullish’ from ‘neutral,’ a day earlier, amid ‘high’ message volumes. Chatter on the platform was up by 200% over the past 24 hours.One user said the trial expansion wouldn’t have taken place if the “safety profile wasn’t looking solid.”<stembedurl>https://stocktwits.com/mattstk2000/message/651253093</stembedurl>Another user was bullish on the company’s prospects for treating pancreatic cancer.<stembedurl>https://stocktwits.com/Pristine_Hurry/message/651252964</stembedurl><h2 class="st-heading-2">Treats First Patient In Europe</h2>Alpha Tau Medical also said it treated the first patient in its ACAPELLA trial, marking the debut of its Alpha DaRT therapy for pancreatic cancer in Europe. The study is testing Alpha DaRT alongside Capecitabine in patients with inoperable, locally advanced disease who have already completed standard chemotherapy.Management said the trial targets a major care gap, as there is currently no standard follow-up treatment for such patients. Pancreatic cancer remains highly lethal, with about 30% of Europe’s 140,000 annual cases diagnosed at this stage.“Over forty thousand Europeans each year are diagnosed with inoperable locally advanced pancreatic cancer, and even if there are some patients who have managed to complete first-line chemotherapy, there remains no established next step, no standard treatment path, and an inevitable progression for the great majority. That is the great unmet need ACAPELLA was designed to address,” CEO Uzi Sofer said.DRTS shares have surged more than 57% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion

The company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.

DRTS Is Back On Retail Radar: These Two Catalysts Are Driving The Rally

Equity

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat...

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 771,223...

Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS

Apella Capital LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2%  - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2% - Still a Buy...

Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS

Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F...

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients with newly diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The ReSTART study is to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, a common form of skin cancer.</li><li>Patient enrollment for both trials is expected to be completed by the end of the first quarter of 2026.</li></ul>Alpha Tau Medical (DRTS) drew strong retail attention on Monday as the oncology therapeutics firm approaches a key catalyst, with markets awaiting crucial patient enrolment data in pancreatic cancer and cutaneous squamous cell carcinoma (cSCC) trials.<a href="https://stocktwits.com/symbol/DRTS">DRTS shares</a> were down 4% in pre-market trading at the time of writing.<h2 class="st-heading-2">IMPACT Study For Pancreatic Cancer</h2>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on those with newly diagnosed, inoperable pancreatic adenocarcinoma. Patient enrollment is expected to be completed by the end of the first quarter of 2026.Participants will continue standard chemotherapy while receiving the company’s Alpha DaRT, a targeted radiation therapy delivered directly into tumors using ultrasound-guided endoscopy.The study aims to evaluate the safety, feasibility, and effectiveness of the treatment, while also tracking tumor response and survival outcomes. Researchers will additionally assess whether some patients with locally advanced disease become eligible for surgery after treatment, a key potential benefit of the therapy, the company said.<h2 class="st-heading-2">ReSTART Trial Targets Skin Cancer Opportunity</h2>Alpha Tau is currently running its multi-center ReSTART study to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. Patient enrollment is expected to be completed in the first quarter of 2026.The trial supports the use of Alpha DaRT, particularly for patients who are not eligible for surgery or standard radiation.The company has already secured Breakthrough Device Designation from the U.S. Food and Drug Administration for this indication, as well as for recurrent glioblastoma multiforme, a type of brain tumor, and oral cavity cancers.This designation reflects the regulator’s view that the therapy could offer significant advantages over existing treatments and allows for an accelerated review and development pathway. It is also part of the FDA’s Total Product Life Cycle Advisory Program.<h2 class="st-heading-2">DRTS Stock: Retail Sentiment Signals High Expectations&nbsp;</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/DRTS_jpg_933216b5d9.webp" alt="DRTS.jpg">Chatter was largely bullish, with one user stating that the company’s current market value could look very low in hindsight if there are further positive updates from the ReSTART trial.<stembedurl>https://stocktwits.com/Joshsim123/message/648904774</stembedurl>Another user said the stock’s current value feels like a “massive mispricing.”<stembedurl>https://stocktwits.com/Jessypenny/message/648902299</stembedurl>Year-to-date, the stock has gained nearly 38%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-gains-california-pipeline-restart-sales/cZERVWqRIZt">Sable Offshore Begins Oil Sales From Highly Scrutinized California Pipeline – SOC Stock Gains 3% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

DRTS Stock Is Back On Retail Radar Ahead Of High-Stakes Cancer Trial Updates

The market is awaiting the company’s patient enrolment data from pancreatic cancer and cutaneous squamous cell carcinoma trials, a key factor in advancing the studies.

Why Alpha Tau Is Back On Traders’ Radar? 

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of "Hold" by Brokerages

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research...

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up   - Here's Why

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's What Happened...

Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting what company leadership described as real and meaningful activity over the...

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Investors are fueling heavy anticipation for the upcoming Digestive Disease Week oral presentation on May 2nd.

The community is buzzing over recent clinical progress, including trial expansions and treating the first European patient.

Bullish sentiment continues to mount as traders target a breakout past the $10 price level.

The company's expansion into European and Japanese markets is seen as a key step toward global commercial validation.

DRTS
ALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DRTS News

DRTSALPHA TAU MEDICAL LTD